Cargando…
1003. BIC/FTC/TAF Maintains Viral Suppression in Patients with Documented M184V/I Mutations: A Real World Experience
BACKGROUND: The M184V/I mutation is a common mutation in treatment-experienced patients with HIV and confers high-level resistance to lamivudine and emtricitabine. Our objective is to assess the effectiveness of bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in a real-world settin...
Autores principales: | Chamberlain, Nicholas, Brock, James B, Mena, Leandro A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776809/ http://dx.doi.org/10.1093/ofid/ofaa439.1189 |
Ejemplares similares
-
Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020) -
2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019) -
1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023) -
1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023) -
Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)